Vancity Investment Management Ltd Boosts Stake in Edwards Lifesciences Corporation $EW

Key Points

• Vancity Investment Management increased its Edwards Lifesciences stake by 15.8% in the second quarter, owning 167,876 shares valued at approximately $15.2 million. Institutional investors collectively hold 79.46% of the company.
• Edwards Lifesciences beat quarterly expectations with earnings of $0.78 per share versus the $0.74 consensus and revenue of $1.74 billion versus $1.70 billion expected; revenue rose 13.6% year over year.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $100.27, while recent targets range as high as $110. Company insiders sold 5,045 shares worth about $457,749 during the past quarter.

Vancity Investment Management Ltd lifted its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 15.8% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 167,876 shares of the medical research company's stock after purchasing an additional 22,881 shares during the quarter. Edwards Lifesciences makes up 2.3% of Vancity Investment Management Ltd's investment portfolio, making the stock its 15th biggest holding. Vancity Investment Management Ltd's holdings in Edwards Lifesciences were worth $15,186,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in EW. Hanson & Doremus Investment Management acquired a new position in Edwards Lifesciences during the first quarter worth approximately $25,000. JPL Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences in the third quarter valued at approximately $25,000. MV Capital Management Inc. acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $26,000. RMG Wealth Management LLC purchased a new position in shares of Edwards Lifesciences during the first quarter worth approximately $26,000. Finally, Pin Oak Investment Advisors Inc. purchased a new position in shares of Edwards Lifesciences during the second quarter worth approximately $26,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $90.00 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. The business has a 50 day simple moving average of $89.73 and a 200-day simple moving average of $85.56. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $96.29. The stock has a market capitalization of $51.82 billion, a PE ratio of 51.72, a price-to-earnings-growth ratio of 2.36 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts' consensus estimates of $0.74 by $0.04. The firm had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. Edwards Lifesciences's quarterly revenue was up 13.6% on a year-over-year basis. During the same period last year, the firm posted $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Analysts Set New Price Targets

EW has been the subject of several research reports. Evercore reiterated an "outperform" rating and issued a $100.00 price target on shares of Edwards Lifesciences in a research report on Monday, July 6th. Royal Bank Of Canada raised their price objective on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock an "outperform" rating in a research report on Monday, July 13th. UBS Group began coverage on shares of Edwards Lifesciences in a research note on Tuesday, July 28th. They issued a "buy" rating and a $110.00 price objective on the stock. Truist Financial upped their target price on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a "hold" rating in a report on Thursday, July 16th. Finally, Weiss Ratings reiterated a "hold (c)" rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. Seventeen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, Edwards Lifesciences currently has a consensus rating of "Moderate Buy" and a consensus target price of $100.27.

Insider Activity

In related news, VP Daniel Lippis sold 619 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the transaction, the vice president directly owned 40,034 shares of the company's stock, valued at $3,684,329.02. This represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Annette Brüls sold 2,644 shares of the stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $89.98, for a total transaction of $237,907.12. Following the transaction, the vice president directly owned 17,984 shares of the company's stock, valued at $1,618,200.32. This represents a 12.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 5,045 shares of company stock valued at $457,749 over the last quarter. Corporate insiders own 0.31% of the company's stock.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source